Strategic acquisitions Lallemand has a track record of expanding capabilities through acquisitions, including BIO-CAT and IFF meat cultures portfolio, signaling ongoing appetite for complementary technology, ingredients, and market reach that could open cross-selling and integration opportunities for fermentation cultures, enzymes, and specialty ingredients.

Enzyme division growth The launch of Solyve, a dedicated Food & Beverage enzyme business, indicates a strategic push into enzyme solutions for F&B processing, creating potential upsell paths for complementary culture-based products, fermentation aids, and technical services.

Meat and fermentation niche Expansion into meat cultures and bioprotective cultures positions Lallemand to partner with processors and brands seeking safer, shelf-stable, and more sustainable fermentation solutions, suggesting sales opportunities in meat, poultry, and ready-to-eat segments.

Health and nutrition focus Recent synbiotic and infant nutrition collaborations, including Baby Gut Support, highlight opportunities to cross-sell across health, gut microbiome, and pediatric product lines to retailers, clinics, and consumer health brands seeking proven probiotic- and synbiotic-based offerings.

Global scale and capabilities With a multinational footprint across 45 countries and a revenue range in the one to ten billion bracket, Lallemand’s scale supports global contracts, co-development programs, and supply agreements for large manufacturers, enabling strategies around regional localization, long-term partnerships, and volume-based pricing.